Search Within

Harold Varmus

  1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (9)
  2. Meeting Abstract (3)
Groups
  1. Department of Medicine (12)
  2. Solid Tumor Oncology Division (12)
  3. Thoracic Oncology (9)
  4. GSK Faculty (7)
  5. Department of Pathology and Laboratory Medicine (6)
  6. Human Oncology and Pathogenesis Program (6)

More Groups

People
  1. Mark Kris (9)
  2. William Pao (7)
  3. Maureen Zakowski (6)
  4. Marc Ladanyi (5)
  5. Vincent Miller (5)
  6. Gregory Riely (4)

More People

Years
  1. 2018 (1)
  2. 2017 (1)
  3. 2010 (1)
  4. 2008 (1)
  5. 2007 (2)
  6. 2005 (4)

More Years

Publications
  1. Journal of Clinical Oncology (2)
  2. PLos Medicine (2)
  3. Proceedings of the National Academy of Sciences of the United States of America (2)
  4. Annals of Oncology (1)
  5. Molecular Carcinogenesis (1)
  6. Molecular and Cellular Biology (1)

More Publications

Publishers
  1. Public Library of Science (3)
  2. American Society of Clinical Oncology (2)
  3. National Academy of Sciences (2)
  4. Nature Publishing Group (2)
  5. American Society for Microbiology (1)
  6. Oxford University Press (1)

More Publishers

Results (12)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics
    Journal Article

    Fan, P. D.; Narzisi, G.; Jayaprakash, A. D.; Venturini, E.; Robine, N.; Smibert, P.; Germer, S.; Yu, H. A.; Jordan, E. J.; Paik, P. K.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2018)

    Fulltext@MSK | Save
  • YES1 amplification as a mechanism of acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKIs) identified by a transposon mutagenesis screen and clinical genomic testing
    Meeting Abstract

    Fan, P. D.; Narzisi, G.; Jayaprakash, A.; Venturini, E.; Robine, N.; Smibert, P.; Germer, S.; Jordan, E.; Wang, L.; Jungbluth, A. A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
    Journal Article

    Barretina, J.; Taylor, B. S.; Banerji, S.; Ramos, A. H.; Lagos-Quintana, M.; Decarolis, P. L.; Shah, K.; Socci, N. D.; Weir, B. A.; Ho, A.; more...
    Nature Genetics (2010)

    Fulltext@MSK | Save
  • The 20th Aspen Cancer Conference: Mechanisms of toxicity, carcinogenesis, cancer prevention, and cancer therapy 2005
    Journal Article

    Bishop, J. M.; Hanahan, D.; Tlsty, T.; Hunter, T.; Lowe, S.; Varmus, H.; Dornbush, K. T.; Waring, J. F.; Jacks, T.; Gilmer, T.; more...
    Molecular Carcinogenesis (2008)

    Fulltext@MSK | Save
  • Characterizing the cancer genome in lung adenocarcinoma
    Journal Article

    Weir, B. A.; Woo, M. S.; Getz, G.; Perner, S.; Ding, L.; Beroukhim, R.; Lin, W. M.; Province, M. A.; Kraja, A.; Johnson, L. A.; more...
    Nature (2007)

    Fulltext@MSK | Save
  • Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4
    Journal Article

    Marks, J. L.; McLellan, M.; Zakowski, M. F.; Lash, A. E.; Kasai, Y.; Broderick, S.; Sarkaria, I. S.; Pham, D.; Singh, B.; Miner, T. L.; more...
    PLoS ONE (2007)

    Fulltext@MSK | Save
  • Mutational profiling of the oncogenome in non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Pao, W.; McLellan, M. D.; Pham, D. K.; Singh, B.; Rusch, V. W.; Zakowski, M. F.; Miller, V. A.; Kris, M. G.; Wilson, R. K.; Varmus, H. E.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
    Journal Article

    Pao, W.; Wang, T. Y.; Riely, G. J.; Miller, V. A.; Pan, Q.; Ladanyi, M.; Zakowski, M. F.; Heelan, R. T.; Kris, M. G.; Varmus, H. E.
    PLos Medicine (2005)

    Fulltext@MSK | Save
  • Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
    Journal Article

    Pao, W.; Miller, V. A.; Politi, K. A.; Riely, G. J.; Somwar, R.; Zakowski, M. F.; Kris, M. G.; Varmus, H.
    PLos Medicine (2005)

    Fulltext@MSK | Save
  • The absence of p53 promotes metastasis in a novel somatic mouse model for hepatocellular carcinoma
    Journal Article

    Lewis, B. C.; Klimstra, D. S.; Socci, N. D.; Xu, S.; Koutcher, J. A.; Varmus, H. E.
    Molecular and Cellular Biology (2005)

    Fulltext@MSK | Save